Latest News & Updates
Durable responses were obtained with the immune checkpoint inhibitor nivolumab, with a manageable safety profile, in a phase II dose-ranging trial conducted in patients with previously treated metastatic renal cell carcinoma (mRCC).
The combination of abiraterone acetate and prednisone has demonstrated a statistically significant improvement in overall survival (OS) for men with metastatic castration-resistant prostate cancer (mCRPC) who had not received prior treatment with chemotherapy
Patients with unresectable melanoma had a significant improvement in the odds of survival when treated in first line with a combination of BRAF and MEK inhibitors, as opposed to anti-BRAF monotherapy
All patients with metastatic colorectal cancer should undergo RAS mutation testing to ensure optimal patient selection for EGFR inhibitor therapy.
Inhibiting BRAF and MEK at the same time improves progression-free survival (PFS) more so than BRAF inhibition alone in patients with BRAF V600 mutation-positive metastatic melanoma, according to results of a phase III placebo-controlled trial.
Latest Peer Exchange Discussions
Experts discuss the next-generation ALK inhibitors ceritinib and AP26113 as treatments for patients with non-small cell lung cancer. View Now
Panelists discuss the use of the newer hormonal agents abiraterone and enzalutamide for the treatment of patients with mCRPC. View Now
Brian Rini, MD, Janice Dutcher, MD, Daniel Heng, MD, MPH, and Charles Henderson, MD, examine factors practitioners consider when treating progressive renal cell carcinoma. View Now
Most Popular Right Now
Online CME Activities